Position in ANIP
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$222,098
+$27,388 QoQ
Shares Held
2,683
+6.0% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#222
of 306 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ANIP Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026MAI Capital Management holds $5,871,377 across 11 Drug Manufacturers - Specialty & Generic names. ANIP ranks #7 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
24,462 | $1,757,838 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
8,096 | $1,364,498 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
1,934 | $1,047,898 | |
| 4 | VTRS |
Viatris Inc
|
32,111 | $509,922 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
8,901 | $301,565 | |
| 6 | HLN |
Haleon plc
|
29,413 | $274,422 | |
| 7 | ANIP |
Ani Pharmaceuticals Inc
This page
|
2,683 | $222,098 | |
| 8 | TAK |
Takeda Pharmaceutical Co Ltd
|
10,292 | $164,979 |
All Filings in ANIP
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $222,098 | 2,683 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $194,710 | 2,532 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $199,086 | 2,522 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $229,000 | 2,500 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $163,125 | 2,500 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $167,375 | 2,500 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $138,200 | 2,500 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||